Genmab A/S (NASDAQ:GMAB) Upgraded at Zacks Research

Zacks Research upgraded shares of Genmab A/S (NASDAQ:GMAB) from a hold rating to a strong-buy rating in a research note published on Thursday,Zacks.com reports.

GMAB has been the subject of a number of other reports. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a report on Saturday, September 27th. Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. HC Wainwright increased their price target on Genmab A/S from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average price target of $40.80.

Genmab A/S Stock Up 4.5%

Shares of NASDAQ GMAB opened at $33.56 on Thursday. The stock’s 50 day moving average price is $25.84 and its two-hundred day moving average price is $22.44. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.61. The stock has a market capitalization of $21.53 billion, a P/E ratio of 16.86, a PEG ratio of 1.90 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Orbis Allan Gray Ltd raised its holdings in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after acquiring an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after buying an additional 2,084,966 shares in the last quarter. First Trust Advisors LP raised its holdings in Genmab A/S by 3.5% during the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after buying an additional 60,504 shares in the last quarter. Brandywine Global Investment Management LLC raised its holdings in Genmab A/S by 1.6% during the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock valued at $36,047,000 after buying an additional 27,372 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its holdings in Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock valued at $24,634,000 after buying an additional 665,893 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.